Neoantigen prioritization based on antigen processing and presentation
Somatic mutations in tumor cells give rise to mutant proteins, fragments of which are often presented by MHC and serve as neoantigens. Neoantigens are tumor-specific and not expressed in healthy tissues, making them attractive targets for T-cell-based cancer immunotherapy. On the other hand, since m...
Saved in:
| Main Authors: | Serina Tokita, Takayuki Kanaseki, Toshihiko Torigoe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1487378/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HLA class II neoantigen presentation for CD4+ T cell surveillance in HLA class II-negative colorectal cancer
by: Satoru Matsumoto, et al.
Published: (2024-12-01) -
Targeting Antigen‐Presenting Cells to Enhance the Tumor‐Spleen Immunity Cycle through Liposome‐Neoantigen Vaccine
by: Yu Xu, et al.
Published: (2025-05-01) -
Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer
by: Joanna Fréderique de Graaf, et al.
Published: (2024-09-01) -
The ubiquitin-like modifier FAT10 is not essential for MHC-I antigen presentation
by: Natalie Pach, et al.
Published: (2025-08-01) -
Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus
by: Chenyi Wang, et al.
Published: (2025-04-01)